Publications
Detailed Information
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Fruchart, Jean-Charles | - |
dc.contributor.author | Santos, Raul D | - |
dc.contributor.author | Aguilar-Salinas, Carlos | - |
dc.contributor.author | Aikawa, Masanori | - |
dc.contributor.author | Al Rasadi, Khalid | - |
dc.contributor.author | Amarenco, Pierre | - |
dc.contributor.author | Barter, Philip J | - |
dc.contributor.author | Ceska, Richard | - |
dc.contributor.author | Corsini, Alberto | - |
dc.contributor.author | Després, Jean-Pierre | - |
dc.contributor.author | Duriez, Patrick | - |
dc.contributor.author | Eckel, Robert H | - |
dc.contributor.author | Ezhov, Marat V | - |
dc.contributor.author | Farnier, Michel | - |
dc.contributor.author | Ginsberg, Henry N | - |
dc.contributor.author | Hermans, Michel P | - |
dc.contributor.author | Ishibashi, Shun | - |
dc.contributor.author | Karpe, Fredrik | - |
dc.contributor.author | Kodama, Tatsuhiko | - |
dc.contributor.author | Koenig, Wolfgang | - |
dc.contributor.author | Krempf, Michel | - |
dc.contributor.author | Lim, Soo | - |
dc.contributor.author | Lorenzatti, Alberto J | - |
dc.contributor.author | McPherson, Ruth | - |
dc.contributor.author | Nuñez-Cortes, Jesus M | - |
dc.contributor.author | Nordestgaard, Børge G | - |
dc.contributor.author | Ogawa, Hisao | - |
dc.contributor.author | Packard, Chris J | - |
dc.contributor.author | Plutzky, Jorge | - |
dc.contributor.author | Ponte-Negretti, Carlos I | - |
dc.contributor.author | Pradhan, Aruna | - |
dc.contributor.author | Ray, Kausik K | - |
dc.contributor.author | Reiner, Željko | - |
dc.contributor.author | Ridker, Paul M | - |
dc.contributor.author | Ruscica, Massimiliano | - |
dc.contributor.author | Sadikot, Shaukat | - |
dc.contributor.author | Shimano, Hitoshi | - |
dc.contributor.author | Sritara, Piyamitr | - |
dc.contributor.author | Stock, Jane K | - |
dc.contributor.author | Su, Ta-Chen | - |
dc.contributor.author | Susekov, Andrey V | - |
dc.contributor.author | Tartar, André | - |
dc.contributor.author | Taskinen, Marja-Riitta | - |
dc.contributor.author | Tenenbaum, Alexander | - |
dc.contributor.author | Tokgözoğlu, Lale S | - |
dc.contributor.author | Tomlinson, Brian | - |
dc.contributor.author | Tybjærg-Hansen, Anne | - |
dc.contributor.author | Valensi, Paul | - |
dc.contributor.author | Vrablík, Michal | - |
dc.contributor.author | Wahli, Walter | - |
dc.contributor.author | Watts, Gerald F | - |
dc.contributor.author | Yamashita, Shizuya | - |
dc.contributor.author | Yokote, Koutaro | - |
dc.contributor.author | Zambon, Alberto | - |
dc.contributor.author | Libby, Peter | - |
dc.date.accessioned | 2019-07-01T05:22:51Z | - |
dc.date.available | 2019-07-01T14:27:53Z | - |
dc.date.issued | 2019-06-04 | - |
dc.identifier.citation | Cardiovascular Diabetology. 18(1):71 | ko_KR |
dc.identifier.issn | 1475-2840 | - |
dc.identifier.uri | https://hdl.handle.net/10371/156075 | - |
dc.description.abstract | In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARMα agonist and concluded that this agent represents a novel therapeutic class, distinct from fibrates, based on pharmacological activity, and, importantly, a safe hepatic and renal profile. The ongoing PROMINENT cardiovascular outcomes trial is testing in 10,000 patients with type 2 diabetes mellitus, elevated triglycerides, and low levels of HDL-C whether treatment with this SPPARMα agonist safely reduces residual cardiovascular risk. | ko_KR |
dc.description.sponsorship | The Consensus Panel members met at a closed expert meeting in Chantilly, France in November 2018 where evidence relating to SPPARMα was critically appraised and discussed. Support for travel was provided by an academic Grant from the R3i. There were no other sources of funding. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | BioMed Central | ko_KR |
dc.subject | Residual cardiovascular risk | ko_KR |
dc.subject | Visceral obesity | ko_KR |
dc.subject | Diabetes | ko_KR |
dc.subject | Atherogenic dyslipidemia | ko_KR |
dc.subject | Triglycerides | ko_KR |
dc.subject | Remnant cholesterol | ko_KR |
dc.subject | Selective peroxisome proliferator-activated receptor alpha modulator | ko_KR |
dc.subject | SPPARMalpha | ko_KR |
dc.subject | Pemafbrate (K-877) | ko_KR |
dc.subject | Infammation | ko_KR |
dc.subject | PROMINENT | ko_KR |
dc.title | The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 임수 | - |
dc.identifier.doi | 10.1186/s12933-019-0864-7 | - |
dc.language.rfc3066 | en | - |
dc.rights.holder | The Author(s) | - |
dc.date.updated | 2019-06-09T03:44:10Z | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.